 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- || LY3325656 / Eli Lilly
Clinical, Journal: Discovery of LY3325656: A GPR142 agonist suitable for clinical testing in human. (Pubmed Central) - Apr 22, 2021
These led to the identification of compound 21 (LY3325656), which demonstrated anti-diabetic benefits in pre-clinical studies and ADME/PK properties suitable for human dosing. Compound 21 is the first GPR142 agonist molecule advancing to phase 1 clinic trials for the treatment of Type 2 diabetes.
- | LY3325656 / Eli Lilly
Trial completion: A Study of LY3325656 in Healthy Participants and Participants With Type 2 Diabetes (clinicaltrials.gov) - Aug 23, 2018
P1, N=80, Completed, Sponsor: Eli Lilly and Company
Compound 21 is the first GPR142 agonist molecule advancing to phase 1 clinic trials for the treatment of Type 2 diabetes. Recruiting --> Completed
- ||| LY3325656 / Eli Lilly
Enrollment open: A Study of LY3325656 in Healthy Participants and Participants With Type 2 Diabetes (clinicaltrials.gov) - Jun 12, 2017
P1, N=80, Recruiting, Sponsor: Eli Lilly and Company
Recruiting --> Completed Not yet recruiting --> Recruiting
- ||| LY3325656 / Eli Lilly
New P1 trial: A Study of LY3325656 in Healthy Participants and Participants With Type 2 Diabetes (clinicaltrials.gov) - Apr 13, 2017
P1, N=80, Not yet recruiting, Sponsor: Eli Lilly and Company